About the Study

DOMINICA: A study of severe pediatric eosinophilic asthma and time to first exacerbation using Benralizumab

This study is for children who are/have: • Ages 6 to 17 • Eosinophilic asthma • Severe or hard to treat asthma • Currently using a high dose maintenance inhaler for at least 6 months • Have gone to urgent care, emergency room or have been hospitalized 3 times in the past year The goal of this study is to see how Benralizumab affects children ages 6 to 17 with eosinophilic asthma that have a history of frequent asthma attacks that are hard to treat with inhaled medication. Benralizumab is approved for children as young as 6 years of age for hard to treat asthma. Researchers want to see how Benralizumab helps the daily life of children with eosinophilic asthma.

Interested in learning more?

Full Study Name: A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)